We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets.
- Authors
Marsh, Glenn A.; McAuley, Alexander J.; Au, Gough G.; Riddell, Sarah; Layton, Daniel; Singanallur, Nagendrakumar B.; Layton, Rachel; Payne, Jean; Durr, Peter A.; Bender, Hannah; Barr, Jennifer A.; Bingham, John; Boyd, Victoria; Brown, Sheree; Bruce, Matthew P.; Burkett, Kathie; Eastwood, Teresa; Edwards, Sarah; Gough, Tamara; Halpin, Kim
- Abstract
Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trials, the efficacy of ChAdOx1 nCoV-19 against SARS-CoV-2 challenge was evaluated in a ferret model of infection. Groups of ferrets received either prime-only or prime-boost administration of ChAdOx1 nCoV-19 via the intramuscular or intranasal route. All ChAdOx1 nCoV-19 administration combinations resulted in significant reductions in viral loads in nasal-wash and oral swab samples. No vaccine-associated adverse events were observed associated with the ChAdOx1 nCoV-19 candidate, with the data from this study suggesting it could be an effective and safe vaccine against COVID-19. Our study also indicates the potential for intranasal administration as a way to further improve the efficacy of this leading vaccine candidate.
- Subjects
SARS-CoV-2; VACCINES; FERRET; INTRANASAL medication; INTRANASAL administration
- Publication
NPJ Vaccines, 2021, Vol 6, Issue 1, p1
- ISSN
2059-0105
- Publication type
Article
- DOI
10.1038/s41541-021-00315-6